References
- Akiyama, H., Kanzaki, H., Tada, J., and Arata, J. 1996. Staphylococcus au- reus infection on cut wounds in the mouse skin: experimenta l staphylococca l botryomycosis. J. Dermatol. Sci. 1:234–238.
- Anwar, H., Dasgupta, M. K., and Costerton, J. W. 1990. Testing the suscepti- bility of bacteria in biofilms to antibacterials. Antimicrob. Agents Chemother. 34:2043–2046.
- Cles, R., Dusart Y., Dupont J. C., Jeanbaptiste B., et al. 1986. Diffusion of oral ofloxacin chromatograph y method. Infection 14 (suppl. 4): S263–S265.
- Gentry, L. O. 1991. Ofloxacin versus parenteral therapy for chronic ostemyelitis. Antimicrob. Agents Chemother. 35:538–541.
- Gristina, A. G., Oga, M., Webb, L. X., and Hobgood, C. D. 1985. Adherent bacterial colonization in the pathogenesi s of osteomyelitis. Science 228:990–993.
- Lamp, K. C., Bailey, E. M., and Rybak, M. J. 1992. Ofloxacin clinical pharma- cokinetics. Clin. Pharmacokine t. 22:32–46.
- Lew, D. P., and Waldvogel, F. A. 1995. Quinolones and osteomyelitis: state of the art. Drugs 49 (suppl. 2):100–111.
- May, T. B., Shinabarger, D., Maharaj, R., et al. 1991. Alginate synthesis by Pseu- domonas aeruginos a: a key pathogeni c factor in chronic pulmonar y infections of cystic fibrosis patients. Clin. Microbiol. Rev. 4:191–206.
- Miller, R. A., Brady, J. M., and Cutright, D. E. 1977. Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolyme r ratios. J. Biomed. Mater. Res. 11:711–719.
- Molinari, G., Pugliese, V., Schito, G. C., and Guzman, C. A. 1996. Bacteria in- volved in the blockage of biliary stents and their susceptibility to antibacterial agents. Eur. J. Clin. Microbiol. Infect. Dis. 15:88–92.
- Morris, W., Steinhoff, M. C., and Russell, P. K. 1994. Potential of polymer microencapsulatio n technolog y for vaccine innovation. Vaccine 12:1–7.
- Ohgaki, N. 1994. Bacterial biofilm in chronic airway infection. Kansenshogaku Zasshi 68:138–151.
- Owusu-Ababio, G., and Rogers, J. A. 1996. Formulation and release kinetics of cephalexin monohydrat e from biodegradabl e polymeri c microspheres. J. Microencapsulation 13:195–205.
- Stratton, C. 1992. Fluoroquinolon e antibiotics: properties of the class and indi- vidual agents. Clin. Therapeutics 14:348–356.
- Suay, D., Tack, K., and Flor, S. 1991. Safety and pharmacokinetic s of a single intravenous ofloxacin in healthy volunteers. Int. J. Clin. Pharm. Res. 11:203–209.
- Walker, R. C., and Wright, A. J. 1991. Symposiun on antimicrobial agents–P artIV. The fluoroquinolones. Mayo Clin. Proc. 66:1249–1259.
- Ward, K. H., Olson, M. E., Lam, K., and Costerton, J. W. 1992. Mechanism of persistent infection associated with peritoneal implants. J. Med. Microbiol. 36:406–413.
- Wolf, R., Ebert, R., Dunky, A. et al. 1984. The clinical pharmacokinetic s and tolerance of enoxacin in healthy volunteers. J. Antimicrobial Chemotherap y (suppl. C):63–69.
- Yuh, J. H., Nightingale, C. H., Quintiliani, R., and Sweeney, K. R. 1991. Bioavail- ability and pharmacokinetic s of ofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 35:384–386.